A new point-of-care colloidal metal immunoassay urine drugs-of-abuse testing device, the BIOSITE TRIAGE | Plus Propoxyphene (TPP), was evaluated for the rapid detection of dextropropoxyphene (PPY) and/or its primary metabolite, norpropoxyphene (NP), in urine at a total PPY/NP concentration of 300 ng/mL or greater. This assay has been added to the Triage device that tests for commonly abused drugs. Adding to drug-free urine PPY and NP established the linearity of the TPP assay at concentrations of 40%, 80%, 120%, and 160% of the cut-off concentration. No significant cross-reactivity was found at 1.0 g/L for 32 drugs commonly encountered in emergency department admissions. Significant cross-reactivity was observed only with diphenhydramine and tricyclic antidepressants. TPP results from 160 urine specimens screened for PPY and/or NP were compared to those obtained by testing with DRI | enzyme immunoassay, Emit II plus immunoassay, Abuscreen | Online immunoassay and gas chromatography-mass spectrometry (GC-MS). There was a 98.8% agreement of positive or negative results between TPP and both the DRI and OnLine assays. The two discordant TPP results were due to concentrations of NP below the TPP minimum cross-reactivity value of 400 ng/mL. These two specimens yielded GC-MS NP concentrations of 262 and 359 ng/mL. These NP concentrations were within • 20% of the cross-reactivity cut-off value for NP for TPP, DRI, and Online. There was only an 88% agreement of positive or negative results between TPP and the Emit assay. Twenty urine specimens yielding PPY positive results when tested by TPP were negative by Emit testing. The discordant TPP results were due to poor cross-reactivity of Emit to NP. A 98.8% agreement of positive PPY results was observed between TPP and GC-MS. Discordant urines were found to contain PPY concentrations below the cut-off value of the assay. TPP was found to be an accurate device for the detection of PPY and NP in urine.
Introduction
Dextro-propoxyphene (propoxyphene) is a mildly effective 9 Author to whom correspondence should be addressed. Alphonse Poklis, Box 98-0165, Medical College of Virginia Station, Richmond, VA 23298-0165. E-mail: apoklis@vcu.edu.
analgesic, somewhat less potent than codeine. Its chemical structure is similar to that of methadone. Side effects during therapy are qualitatively similar to those of codeine, but the incidence of gastrointestinal side effects such as nausea, anorexia, constipation, and abdominal pain are somewhat lower with propoxyphene. However, the two drugs seem equally likely to cause drowsiness. Propoxyphene has no significant antipyretic, anti-inflammatory or anti-tussive actions (1) . Propoxyphene is metabolized primarily via N-demethylation to norpropoxyphene, which is one-fourth to one-half as active an analgesic as propoxyphene (2) . Despite the recent increase in use of semi-synthetic narcotic analgesics such as oxycodone and hydrocodone, propoxyphene remains a popular prescription drug for relief of moderate pain. Propoxyphene is among the most commonly encountered drugs associated with emergency department visits (3) . Overdose with propoxyphene can result in stupor, coma, convulsions, respiratory depression, cardiac arrhythmias, hypotension, pulmonary edema, and circulatory collapse. Although naloxone has been recommended for use in the treatment of propoxyphene overdose, its use in clinical situations has been reported ineffective. Based on norpropoxyphene's toxicity in animals and its resistance to naloxone, it is thought that norpropoxyphene is at least partially responsible for the toxic effects of propoxyphene in humans, especially the cardiotoxicity (4). The detection of propoxyphene in urine of patients with suspected overdose is helpful in confirming the diagnosis and in selecting appropriate treatment.
The TRIAGE panel for drugs of abuse (BIOSITE Diagnostic, San Diego, CA) is a colloidal metal immunoassay on-site testing device for rapid urinary drugs-of-abuse testing. The device is a test card impregnated with antibodies in separate areas to simultaneously detect seven drug or classes of drugs: amphetamines, barbiturates, benzodiazepines, cocaine metabolite, opiates, marijuana metabolite, phencyclidine, and tricyclic antidepressants (5) (6) (7) (8) (9) . This study evaluated the use of the TRIAGE PPY (TPP), a card which has added to it an area with antibodies that react to combined propoxyphene and/or norpropoxyphene at a concentration of 300 ng/mL or greater.
Materials and Methods

Reagents
All primary reference materials of propoxyphene and other drugs were obtained from Sigma Chemical Company (St. Louis, MO) or were gifts of their respective pharmaceutical manufacturers. Drug-free urine was collected from laboratory personnel and with the exception of caffeine or nicotine metabolites, tested negative for all drugs in this study. Neither caffeine nor nicotine metabolites interfered with any assay in the study.
TRIAGE PLUS PPY immunoassay
TPP devices were used according to manufacturer's instructions (Biosite, San Diego, CA). All materials necessary for the assay are provided with the kits. Briefly, the cap was removed from the reaction cup on the bottom of the device and using a provided pipette, 140 IJL of urine were transferred into the cup. The card has three different labeled areas: two areas impregnated with procedural control material labeled "CONTROL NEGATIVE" and "CONTROL POSITIVE", and the "Drug Detection Area" which contains discreet labeled zones of impregnated antibodies for the drugs tested. The urine was incubate 10 rain at room temperature. Using the pipette and a clean tip, the reaction mixture was transferred to the area of the card labeled Drug Detection Area. The mixture was allowed to completely soak into the reaction area. Three drops of provided "Wash Solution" was then added and allow to completely wet the reaction area. A positive result produces a red colored bar in the Drug Detection Area next to the drug name indicated. For the assay to be valid, CONTROL POSITIVE must have a red bar and CONTROL NEGATIVE must be blank or unreactive. The cut-off concentration of the assay for propoxyphene was 300 ng/mL or greater. The manufacturer states that a concentration of 400 ng/mL norpropoxyphene will yield a response equal to that of 300 ng/mL of propoxyphene.
In order to evaluate the response of the assay, the following scoring system was applied to positive reactions in the propoxyphene zone: a red bar with an intensity less than that of the CONTROL POSITIVE was scored (+) positive; if the intensity of the response was approximately equal to that of the CONTROL POSITIVE, the result was (++) positive; and if the response was markedly greater that the CONTROL POSITIVE, the result was scored (+++) positive.
DRI enzyme immunoassay
The DRI propoxyphene assays were obtained from Diagnostic Reagents, Inc (Sunnyvale, CA). All DRI assays were preformed on Hitachi 717 Automatic Analyzer as recommended by the manufacturer. The assay was calibrated with negative and cutoff calibrators containing 0.0 and 300 ng/mL of propoxyphene, respectively. Control urines containing 0, 225, and 375 ng/mL propoxyphene were obtained from Diagnostic Reagents, Inc. The manufacturer states that a concentration of 500 ng/mL norpropoxyphene will yield a response equal to that of 300 ng/mL of propoxyphene.
EMIT II plus immunoassay
The Emit propoxyphene assays were obtained from Syva
Company (Dade Behring, Cupertino, CA). All Emit assays were preformed on a Syva 30R Analyzer as recommended by the manufacturer. The assay'was calibrated with negative, cut-off and medium calibrators containing 0.0, 300, and 500 ng/mL of propoxyphene, respectively. Control urines containing 0, 240, and 360 ng/mL of propoxyphene obtained from Quality Assurance Services (Augusta, GA) were included in each batch of specimens. The manufacturer states that a concentration of 800 ng/mL norpropoxyphene will yield a response equal to that of 300 ng/mL of propoxyphene.
Abuscreen Online immunoassay
The Online propoxyphene assays were obtained from Roche Diagnostics Corp. (Indianapolis, IN) . All assays were performed on a Hitachi 747 Automatic Analyzer (Boehringer Mannheim, Indianapolis, IN) as recommended by the manufacturer. The assay was calibrated with negative, cut-off, and medium calibrators containing 0.0, 300, and 500 ng/mL of propoxyphene, respectively. Control urines containing 0, 240, and 360 ng/mL propoxyphene obtained from Quality Assurance Services (Augusta, GA) were included in each batch of specimens. The manufacturer states that a concentration of 500 ng/mL norpropoxyphene will yield a response equal to that of 300 ng/mL of propoxyphene.
Criteria for positive immunoassay
For each immunoassay a rate equal to or greater than that of the 300 ng/mL propoxyphene cut-off calibrator was considered a positive result. All immunoassay reagents were stored refrigerated at 2~
Gas chromatography-mass spectrometry (GC-MS)
Propoxyphene and norpropoxyphene and added deuterated propoxyphene and norpropoxyphene internal standards were isolated from urine by solid-phase extraction in a Detectabuse TM Gravity GV-65 column as described by the manufacturer (Biochemical Diagnostics Corp., Edgewood, NY ). The specimens were analyzed in a Hewlett-Packard (Palo Alto, CA) 6890 GC with a spliEsplitless injection port, a 7673 autosampler and a 5993A mass selective detector (MSD). The column was an HP-5 MS capillary column (30 m x 0.25 ram, 0.25-1Jm film thickness). The oven temperature program was 150~ held for 2 rain, then ramped at 15~ to 280~ The MSD was operated in the SIM mode using the following ions: propoxyphene, 250, 265, and 178; norpropoxyphene cyclic amide, 105, 220 and 77; 2H5-propoxyphene 255 and 270; and 2H5-norpropoxyphene cyclic amide, 239 and 240. The lower limit of quantification of each analyte was 150 ng/mL.
Evaluation protocol
The linearity of the TPP assay was determined by adding known amounts of propoxyphene and norpropoxyphene to drug-free urine at concentrations above and below their stated cut-off values. The selectivity of the assay was determined by adding to drug-free urine known concentrations of 32 drugs or drug metabolites commonly encountered in urine drug testing. These urines were then analyzed by the TPP assay and the response noted. The clinical performance of TPP was evaluated by comparing the results for propoxyphene and norpropoxyphene obtained by testing with those of DRI enzyme immunoassay, Emit II plus enzyme immunoassay, Abuscreen OnLine microparticle immunoassay, and GC-MS. Two series of urine specimens were obtained for this study. Aliquots of 98 urines submitted for employee drug testing or other forensic testing that tested positive for the presence of propoxyphene by DRI enzyme immunoassay were collected over an eight-week period for additional testing. These samples were then tested by TPP, Emit, OnLine, and GC-MS. An additional group of 62 consecutive urine specimens received for clinical testing were then analyzed by each of the assays.
Results and Discussion
The TPP assay demonstrated good linearity around the stated cut-off value, as propoxyphene added urine tested at 300 ng/mL, 360 ng/mL (120% of the cut-off) and 420 ng/mL (140% of the cut-off) yielded a clearly positive result equal in color intensity to the "positive control" color (++ response). At propoxyphene concentrations of 60% and 80% of the cut-off value (180 and 240 ng/mL, respectively) only negative results were obtained, that is, no color developed in the propoxyphene test area of the device.
The manufacturer of TPP lists over 450 drugs that did not cross-react with the TPP at urinary concentrations of 100 mg/L. We tested 32 drugs commonly found in emergency room admissions (4) at 10 times this concentration, 1000 mg/L, and found little significant cross-reactivity (Tables I and II) . A few compounds yielded a (+) positive response; however, 1000 mg/L far exceeds the urine concentrations found in massive overdoses Nortriptyline Doxepin of these drugs. However, diphenhydramine, amitriptyline, doxepin, imipramine, and nortriptyline were found to cross-react with the TPP assay at concentrations of 100 mg/L. It should be noted that this concentration exceeds accepted urine values at therapeutic doses of these drugs. Even in cases of massive antidepressant overdose, urine values of amitriptyline, imipramine, doxepin, and nortriptyline would not be expected to be at concentrations of 100 mg/L.
The results of propoxyphene testing of the urine specimens by the TPP device and the other three immunoassays are presented in Figure 1 . There was a 98.8% agreement of positive or negative results between TPP and both the DRI and OnLine assays. There was a complete agreement of findings between DRI and OnLine. The two discordant TPP results were due to concentrations of norpropoxyphene below the TPP minimum cross-reactivity value of 400 ng/mL. These two specimens yielded GC-MS norpropoxyphene concentrations of 262 and 359 ng/mL. The norpropoxyphene concentrations were within • 20% of the cross-reactivity cut-off value for norpropoxyphene for TPP, DRI, and Online. Therefore, there was an equal chance that any of these three assays would yield positive or negative results for the two discordant specimens.
There was only an 88% agreement of positive or negative results between TPP and the Emit assay. Twenty urine specimens yielding propoxyphene-positive results when tested by TPP were negative by Emit testing. Parent propoxyphene was not present in these 20 specimens. The discordant TPP results were due to poor cross-reactivity of Emit to norpropoxyphene. Emit has a stated reactivity cut-off of 800 ng/mL for norpropoxyphene. Sixteen of the discordant specimens yielded GC-MS norpropoxyphene concentrations of 300 to 890 ng/mL. Therefore, the negative results yielded by Emit testing were consistent with its low sensitivity to norpropoxyphene. However, four of the discordant specimens had norpropoxyphene values of 1000 to 1700 ng/mL. This poor cross-reactivity of Emit to norpropoxyphene has been previously reported (10) . One hundred of the study urine specimens were positive for propoxyphene or norpropoxyphene when tested by GC-MS at a cut-off concentration of 150 ng/mL. There was a 98.8% agreement of positive or negative results between TPP and the GC-MS assay. The two discordant TPP results were due to concentrations of norpropoxyphene below the TPP minimum crossreactivity value of 400 ng/mL. These specimens contained 260 ng/mL and 360 ng/mL of norpropoxyphene.
Comparison of TPP and DRI test results
DRI
The incidence of the other drugs detected by the TPP device in urine specimens testing positive for propoxyphene was as follows: barbiturates, 2; benzodiazepines, 5; cocaine metabolite, 8; opiates, 8; and tetrahydrocannabinol carboxylic acid, 2. Amphetamine, phencyclidine, and tricyclic antidepressants were not detected in any of the specimens. The presence of these drugs did not interfere with the detection of propoxyphene by the TPP assay. The incidence of drugs detected in urine specimens testing negative for propoxyphene was as follows: barbiturates, 2; benzodiazepines, 5; cocaine metabolite, 6; and opiates, 6. Amphetamine, phencyclidine, THC acid, and tricyclic antidepressants were not detected in any of the propoxyphene negative specimens. The presence of these drugs did produce a false-positive propoxyphene result by the TPP assay.
Conclusions
We found the TPP an accurate device for the detection of propoxyphene and/or norpropoxyphene in urine yielding results comparable to DRI and OnLine immunoassays with a cutoff value of 300 ng/mL PPY. The addition to PPY to the colloidal metal immunoassay device allows the simultaneous detection of eight common drugs or drug classes in a single aliquot of urine within 10 rain. With the exception of very high concentrations of diphenhydramine and tricyclic anti-depressant drugs the TPP assay has no cross-reactivity with other drugs commonly encountered in emergency department admissions.
